Concepedia

Noncleavable Linkers

"Noncleavable Linker" is a type of chemical moiety in antibody-drug conjugates that stably connects the antibody to the cytotoxic payload without undergoing cleavage in the extracellular or intracellular environment, thereby requiring complete antibody degradation to release the active drug.

39

Publications

2.4K

Citations

439

Authors

80

Institutions

Publications per year

2017–2026

19

Variants

Noncleavable Linker

Parents

Publications

39

A general approach to site-specific antibody drug conjugates

Feng Tian, Yingchun Lu, Anthony Manibusan et al. · Proceedings of the National Academy of Sciences · 2014 · 317 citations · Full text

, , +17

A Yoctoliter-Scale DNA Reactor for Small-Molecule Evolution

Margit Haahr Hansen, Peter Blakskjær, L. Petersen et al. · Journal of the American Chemical Society · 2009 · 190 citations · Full text

, , +17

SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm

Kevin J. Hamblett, Allison P. Jacob, Jesse L. Gurgel et al. · Cancer Research · 2015 · 135 citations

, , +17

LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence

Xing Gong, Ali Azhdarinia, Sukhen C. Ghosh et al. · Molecular Cancer Therapeutics · 2016 · 129 citations

, , +17

Trastuzumab Emtansine: A Novel Antibody–Drug Conjugate for HER2-Positive Breast Cancer

Ian E. Krop, Eric P. Winer · Clinical Cancer Research · 2013 · 102 citations

, , +17

1–5 of 39

Authors

439

  1. KJ
    Kevin J. Hamblett

    Seagen (United States), United States

    4 publications · 308 citations

    4

    h-index

  2. DA
    Dan A. Rock

    Amgen (United States), United States

    4 publications · 242 citations

    4

    h-index

  3. WC
    William C. Fanslow

    Research & Development Corporation, Canada

    4 publications · 308 citations

    4

    h-index

  4. BM
    Brooke M. Rock

    Amgen (United States), United States

    3 publications · 208 citations

    3

    h-index

  5. SS
    Sophia Siu

    Amgen (United States), United States

    3 publications · 279 citations

    3

    h-index

1–5 of 439

Institutions

80

  1. Amgen (United States)

    Thousand Oaks, United States

    5 h-index

    41 publications

    3.1K citations

  2. Pfizer (United States)

    New York, United States

    3 h-index

    26 publications

    2.5K citations

  3. ImmunoGen (United States)

    Waltham, United States

    3 h-index

    25 publications

    928 citations

  4. Novartis (Switzerland)

    Basel, Switzerland

    3 h-index

    30 publications

    648 citations

  5. American Institutes for Research

    Alexandria, United States

    2 h-index

    12 publications

    846 citations

  6. Stanford University

    Stanford, United States

    2 h-index

    5 publications

    153 citations

  7. Spirogen (United Kingdom)

    London, United Kingdom

    2 h-index

    8 publications

    496 citations

  8. University of Santa Monica

    Santa Monica, United States

    2 h-index

    33 publications

    2.1K citations

1–8 of 80

Venues

  1. Molecular Cancer Therapeutics

    MCT · 9 publications · 489 citations

    9

    h-index

  2. Clinical Cancer Research

    4 publications · 301 citations

    4

    h-index

  3. Bioconjugate Chemistry

    4 publications · 149 citations

    4

    h-index

  4. Drug Metabolism and Disposition

    2 publications · 63 citations

    2

    h-index

  5. ChemBioChem

    2 publications · 71 citations

    2

    h-index

1–5